Randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetic Characteristics of Pregabalin According to Different Controlled Released Formulations in Healthy Male Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
28
Participants
Timeline
Start Date
August 31, 2011
Primary Completion Date
August 31, 2011
Study Completion Date
August 31, 2011
Conditions
Healthy
Interventions
DRUG
Pregabalin
Pregabalin 300mg a day
Trial Locations (1)
Unknown
Seoul ST.Mary Hospital, Seoul
All Listed Sponsors
lead
Yuhan Corporation
INDUSTRY
NCT01420913 - Randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetic Characteristics of Pregabalin According to Different Controlled Released Formulations in Healthy Male Subjects | Biotech Hunter | Biotech Hunter